Literature DB >> 588801

The mode of action of tetrabenazine on peripheral noradrenergic nerves.

D R Tomlinson.   

Abstract

1. Tetrabenazine (100 mg/kg i.p. in rats) greatly decreased catecholamine-induced histofluorescence in the iris, hepatic portal vein, inferior vena cava and mesenteric blood vessels 4 h after injection. Fluorescence returned to normal by 24 h after injection. 2. The extent of this depletion (4 h after tetrabenazine) was similar to that seen 18 h after reserpine (0.5 mg/kg i.p.). 3. Incubation of tissues taken from rats 4 h after this dose of tetrabenazine with noradrenaline 5 X 10(-6)M restored the intraneuronal fluorescence as well as the electron density of noradrenergic vesicle cores viewed with the electron microscope. No such repletion was seen on incubation of tissues from reserpine-treated rats with noradrenaline under the same conditions. 4. Incubation of tetrabenazine-treated hepatic portal veins with noradrenaline also reinstated the normal response to electrical stimulation of the intramural nerves. This did not occur with reserpine-treated veins. 5. The interpretation that tetrabenazine exerts a reversible depleting effect on the noradrenergic vesicle is supported by the demonstration that it exerts no monoamine oxidase inhibiton.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 588801      PMCID: PMC1667862          DOI: 10.1111/j.1476-5381.1977.tb08425.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  THE FINE STRUCTURE OF THE ALBINO RABBIT IRIS WITH SPECIAL REFERENCE TO THE IDENTIFICATION OF ADRENERGIC AND CHOLINERGIC NERVES AND NERVE ENDINGS IN ITS INTRINSIC MUSCLES.

Authors:  K C RICHARDSON
Journal:  Am J Anat       Date:  1964-03

2.  UPTAKE OF L-DOPA AND NORADRENALINE BY CENTRAL CATECHOLAMINE NEURONS.

Authors:  K FUXE; N A HILLARP
Journal:  Life Sci (1962)       Date:  1964-12

3.  [THE EFFECT OF DRUGS ON THE ELIMINATION OF NORADRENALIN FROM PERFUSION FLUID AND NORADRENALIN UPTAKE IN THE ISOLATED HEART].

Authors:  R LINDMAR; E MUSCHOLL
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1964-07-28

4.  SITE OF ACTION OF RESERPINE.

Authors:  A DAHLSTROEM; K FUXE; N A HILLARP
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1965

5.  An examination of the action of tetrabenazine on peripheral noradrenergic neurones [proceedings].

Authors:  D R Tomlinson
Journal:  Br J Pharmacol       Date:  1977-06       Impact factor: 8.739

6.  The depletion and recovery of noradrenaline in the brain and some sympathetically innervated mammalian tissues after tetrabenazine.

Authors:  J Häggendal
Journal:  J Pharm Pharmacol       Date:  1968-05       Impact factor: 3.765

7.  A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.

Authors:  D L McLellan; R J Chalmers; R H Johnson
Journal:  Lancet       Date:  1974-01-26       Impact factor: 79.321

8.  Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects.

Authors:  G P QUINN; P A SHORE; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1959-10       Impact factor: 4.030

9.  Ultrastructural cytochemistry of biogenic amines in nervous tissue: methodologic improvements.

Authors:  J P Tranzer; J G Richards
Journal:  J Histochem Cytochem       Date:  1976-11       Impact factor: 2.479

10.  The use of lead citrate at high pH as an electron-opaque stain in electron microscopy.

Authors:  E S REYNOLDS
Journal:  J Cell Biol       Date:  1963-04       Impact factor: 10.539

View more
  3 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 2.  Tourette's syndrome and role of tetrabenazine: review and personal experience.

Authors:  Mauro Porta; Marco Sassi; Mario Cavallazzi; Maurizio Fornari; Arianna Brambilla; Domenico Servello
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 3.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.